At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
Elotuzumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
In Brief
A Phase 2 clinical trial evaluating Elotuzumab, Lenalidomide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 84 participants across 29 sites.
Detailed Summary
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedJun 2014
Primary CompletionJun 2016
Study CompletionJul 2018
TodayJul 2026
First PostedJun 9, 2014
Enrollment StartMar 8, 2014
Primary CompletionJun 30, 2016
Study CompletionJul 11, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.1 years ago
Interventions
Elotuzumabdrug
Lenalidomidedrug
Dexamethasonedrug